EMA Withdrawn: Sprimeo (aliskiren) — Novartis Europharm Ltd.

View source ↗

Summary

EMA withdrew Sprimeo (aliskiren) from the European market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Sprimeo (aliskiren)

Snippet

Status: Withdrawn. Therapeutic area: Hypertension. MAH: Novartis Europharm Ltd.. Decision date: 04/07/2012